Skip to content
18 November · 06:30 UTCFollow GSK by emailFollow

GSK · story · 18 November

Nelkarmi receives US accelerated approval for ALK-positive lung cancer

GSK · 22 headlines from 19 outlets, on 18 November 2026.

The story

+9.5strongly positive
Headlines22
Outlets19
Days118 November

Outlets report that Nelkarmi (neladalkib), the second lung cancer medicine GSK has gained from buying Nuvalent, received accelerated US approval.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

How each outlet covered it · 19 outlets

The 10 outlets with the most impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

The 10 outlets with the most impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outletAverage tone
FT Companies10.0
TradingView9.3
Investing.com9.2
Bloomberg10.0
Reuters10.0
Fierce Pharma10.0
PRESS Insider10.0
Traders Union10.0
FirstWord Pharma9.7
Quartz9.7
OutletHeadlinesAverage tone
FT Companies2+10.0
TradingView2+9.3
Investing.com2+9.2
Bloomberg1+10.0
Reuters1+10.0
Fierce Pharma1+10.0
PRESS Insider1+10.0
Traders Union1+10.0
FirstWord Pharma1+9.7
Quartz1+9.7
All 19 outlets
OutletHeadlinesAverage tone
Seeking Alpha1+9.5
grafa.com1+9.5
London South East1+9.2
Yahoo Finance1+9.2
GenomeWeb1+9.0
StreetInsider1+8.7
tokenpost.com1+8.7
Financial Times1+8.3
Breakingthenews.net1+8.3

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Day by day · 1 day, strongest headlines first

Wednesday 18 November 202622 headlines · Outlets report that Nelkarmi (neladalkib), the second lung cancer medicine GSK has gained from buying Nuvalent, received accelerated US approval.+9.5
ToneWhat the article reported, and why it scored that waySource
+10.0Approved drug seen as having very large sales potential.Bloomberg (opens the article) ↗
+10.0Second product from major acquisition gains US clearance.Reuters (opens the article) ↗
+10.0Second approval from large acquisition supports its value.FT Companies (opens the article) ↗
+10.0Second approval from large acquisition supports its value.FT Companies (opens the article) ↗
+10.0Second acquired lung cancer drug clears regulator.Fierce Pharma (opens the article) ↗
+10.0Regulatory clearance for second cancer medicine from acquired portfolio.PRESS Insider (opens the article) ↗
+10.0Approval bolsters its growing cancer franchise.Traders Union (opens the article) ↗
+10.0Approval from major deal adds to oncology line-up.TradingView (opens the article) ↗
14 more headlines that day
ToneWhat the article reported, and why it scored that waySource
+9.7Acquisition delivers another marketed oncology product.FirstWord Pharma (opens the article) ↗
+9.7Second lung cancer product cleared following acquisition.Quartz (opens the article) ↗
+9.5Regulator clears therapy gained through takeover.Seeking Alpha (opens the article) ↗
+9.5US regulator clears new lung cancer medicine.grafa.com (opens the article) ↗
+9.2Accelerated US clearance for new lung cancer treatment.London South East (opens the article) ↗
+9.2Approval for previously treated ALK-positive patients.Investing.com (opens the article) ↗
+9.2US regulator approves its lung cancer medicine.Investing.com (opens the article) ↗
+9.2Company announces US approval for advanced lung cancer treatment.Yahoo Finance (opens the article) ↗
+9.0Approval addresses resistance in a lung cancer subtype.GenomeWeb (opens the article) ↗
+8.7Conditional US clearance for lung cancer drug.TradingView (opens the article) ↗
+8.7Conditional US clearance for lung cancer drug.StreetInsider (opens the article) ↗
+8.7Conditional US approval for lung cancer drug.tokenpost.com (opens the article) ↗
+8.3US regulators clear its cancer medicine.Financial Times (opens the article) ↗
+8.3Brief report of US regulatory clearance.Breakingthenews.net (opens the article) ↗

Follow by email

A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 18 November · 867 headlines · 94 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt